Regeneron Pharmaceuticals Forecast, price target & analysts
Regeneron Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Regeneron Pharmaceuticals Classifications & Recommendation
Regeneron Pharmaceuticals Price Target
| Target Price | $867.00 |
| Price | $742.12 |
| Potential | 16.83% |
| Number of Estimates | 33 |
| 33 Analysts have issued a price target Regeneron Pharmaceuticals 2027 . The average Regeneron Pharmaceuticals target price is $867.00. This is 16.83% higher than the current stock price. The highest price target is $1,081.50 45.73% , the lowest is $666.60 10.18% . | |
| A rating was issued by 38 analysts: 26 Analysts recommend Regeneron Pharmaceuticals to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2027 of 16.83% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
31 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2026. The average Regeneron Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Regeneron Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
32 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Regeneron Pharmaceuticals...
Current Regeneron Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Argus Research |
Hold
➜
Buy
|
Upgrade | Oct 01 2026 |
| Jefferies |
Buy
➜
Buy
|
Unchanged | Oct 01 2026 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Sep 29 2026 |
| HSBC |
Buy
➜
Buy
|
Unchanged | Sep 10 2026 |
| Leerink Partners |
Market Perform
➜
Market Perform
|
Unchanged | Aug 17 2026 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 03 2026 |
| Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 03 2026 |
| Analyst Rating | Date |
|---|---|
|
Upgrade
Argus Research:
Hold
➜
Buy
|
Oct 01 2026 |
|
Unchanged
Jefferies:
Buy
➜
Buy
|
Oct 01 2026 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Sep 29 2026 |
|
Unchanged
HSBC:
Buy
➜
Buy
|
Sep 10 2026 |
|
Unchanged
Leerink Partners:
Market Perform
➜
Market Perform
|
Aug 17 2026 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 03 2026 |
|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 03 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
